PENTAMORPHONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H28N2O3
Molecular Weight	368.4693
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12OC3=C(O)C=CC4=C3[C@@]15CCN(C)[C@H](C4)[C@]5(NCCCCC)C=CC2=O

InChI

InChIKey=NRPCWSUJMWEFOK-KDXIVRHGSA-N

InChI=1S/C22H28N2O3/c1-3-4-5-11-23-22-9-8-16(26)20-21(22)10-12-24(2)17(22)13-14-6-7-15(25)19(27-20)18(14)21/h6-9,17,20,23,25H,3-5,10-13H2,1-2H3/t17-,20+,21+,22-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H28N2O3
Molecular Weight	368.4693
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1708214 | https://www.ncbi.nlm.nih.gov/pubmed/1698039 | https://www.ncbi.nlm.nih.gov/pubmed/2465708

Pentamorphone was developed as a highly potent opioid with rapid onset and short duration of action that has been reported to produce analgesia with limited depression of ventilation. Pentamorphone participated in a clinical trial for the management of postoperative pain. However, no acute cardiorespiratory changes were observed. The drug was ineffective for treating acute postoperative pain after major surgery. In addition, was shown that pentamorphone, 10 micrograms/kg, does not seem to offer any significant advantage over opioids currently used for anesthesia in patients undergoing elective coronary artery bypass grafting (CABG). That is why its further development was discontinued.

Approval Year

PubMed

Title	Date	PubMed
Evaluation of pentamorphone in humans: a new potent opiate.	1989 Mar	2465708
Cardiovascular effects of large doses of pentamorphone in the dog.	1990 Jun	1720033
Depression of ventilatory responses to hypoxia and hypercapnia after pentamorphone.	1990 Oct	1698039
Pharmacodynamics of pentamorphone during coronary artery bypass grafting in humans.	1992 Apr	1373660
A comparison of pentamorphone and fentanyl in balanced anaesthesia during general surgery.	1994 Aug	7522977

Sample Use Guides

In Vivo Use Guide

double-blind study of 72 patients given 0.08, 0.16, or 0.24 micrograms/kg of pentamorphone or a placebo intravenously in the recovery room after major abdominal or orthopedic surgery.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:16:20 GMT 2023` Edited by `admin` on `Fri Dec 15 15:16:20 GMT 2023`
Record UNII	MM4487B4MW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PENTAMORPHONE

Official Name

English

14B-N-PENTYLAMINOMORPHINONE

Common Name

English

A-4492

Code

English

MORPHINAN-6-ONE, 7,8-DIDEHYDRO-4,5-EPOXY-3-HYDROXY-17-METHYL-14-(PENTYLAMINO)-, (5.ALPHA.)-

Systematic Name

English

PENTAMORPHONE [MART.]

Common Name

English

pentamorphone [INN]

Common Name

English

RX77989

Code

English

PENTAMORPHONE [USAN]

Common Name

English

RX-77989

Code

English

Code System Code Type Description

PUBCHEM

5464186